Published in Cutis on September 01, 2010
An open label prospective randomized trial to compare the efficacy of coal tar-salicylic Acid ointment versus calcipotriol/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis. Indian J Dermatol (2014) 2.03
Effectiveness and Patient Acceptance of Halcinonide 0.1% Cream in 216g Jars for Large-area Steroid-responsive Dermatoses. J Clin Aesthet Dermatol (2011) 0.75
Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict. Dermatol Ther (Heidelb) (2016) 0.75
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol (2010) 8.55
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet (2008) 5.85
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol (2008) 3.95
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet (2003) 3.52
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc (2004) 3.40
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med (2014) 3.36
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol (2003) 3.22
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
Adherence, the fourth dimension in the geometry of dermatological treatment. Arch Dermatol (2009) 2.91
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
In the United States, blacks and Asian/Pacific Islanders are more likely than whites to seek medical care for atopic dermatitis. Arch Dermatol (2002) 2.75
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks. J Am Acad Dermatol (2009) 2.65
Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol (2013) 2.58
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 2.50
Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol (2013) 2.38
National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol (2007) 2.29
The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol (2005) 2.26
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol (2009) 2.21
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol (2008) 2.19
PSORS2 is due to mutations in CARD14. Am J Hum Genet (2012) 2.10
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol (2004) 2.05
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol (2013) 2.01
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
Memory regulatory T cells reside in human skin. J Clin Invest (2014) 1.95
The prevalence of acne in adults 20 years and older. J Am Acad Dermatol (2007) 1.94
Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol (2004) 1.94
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol (2009) 1.94
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol (2007) 1.76
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76
Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet (2011) 1.74
A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol (2011) 1.73
The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol (2005) 1.68
Trichotillomania. Dermatol Ther (2008) 1.68
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
Adherence in dermatology: a review of the last 20 years. J Dermatolog Treat (2006) 1.64
Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol (2003) 1.60
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
Drug samples in dermatology: special considerations and recommendations for the future. J Am Acad Dermatol (2010) 1.55
Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol (2010) 1.53
Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol (2004) 1.53
Cardiocutaneous syndromes and associations. J Am Acad Dermatol (2002) 1.53
Written action plans: potential for improving outcomes in children with atopic dermatitis. J Am Acad Dermatol (2008) 1.52
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum (2005) 1.51
Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol (2007) 1.51
A randomized controlled pilot study of the effects of an extra office visit on adherence and outcomes in atopic dermatitis. Arch Dermatol (2010) 1.50
Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol (2007) 1.50
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol (2009) 1.48
UV light abuse as a substance-related disorder: clinical implications. Arch Dermatol (2008) 1.48
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol (2009) 1.45
Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol (2005) 1.45
Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol (2004) 1.45
Trends in pediatric psoriasis outpatient health care delivery in the United States. Arch Dermatol (2011) 1.44
Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol (2006) 1.44
Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol (2006) 1.43
Treatment of psoriasis in children: is there a role for antibiotic therapy and tonsillectomy? Pediatr Dermatol (2003) 1.43
Hyperpigmentation: an overview of the common afflictions. Dermatol Nurs (2004) 1.43
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol (2008) 1.43
Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol (2012) 1.43
Dermatosis neglecta: a series of case reports and review of other dirty-appearing dermatoses. Dermatol Online J (2006) 1.42
Morgellons disease: a rapport-enhancing term for delusions of parasitosis. J Am Acad Dermatol (2006) 1.42
Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol (2005) 1.42
Trends in Mohs surgery from 1995 to 2010: an analysis of nationally representative data. Dermatol Surg (2015) 1.42
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. J Clin Aesthet Dermatol (2011) 1.40
How much of a topical agent should be prescribed for children of different sizes? J Dermatolog Treat (2006) 1.40
Adherence with topical treatment is poor compared with adherence with oral agents: implications for effective clinical use of topical agents. J Am Acad Dermatol (2006) 1.40
National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol (2008) 1.40
Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners. J Am Acad Dermatol (2006) 1.40
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol (2012) 1.40
Where did current academic dermatologists train? J Am Acad Dermatol (2010) 1.39
Use of Ber-EP4 protein in recurrent metastatic basal cell carcinoma: a case report and review of the literature. Int J Dermatol (2004) 1.39
Increase in procedures performed at dermatology office visits from 1995 to 2001. Dermatol Surg (2005) 1.39
Hat-wearing patterns in persons attending baseball games. J Am Acad Dermatol (2006) 1.39
Goeckerman regimen for management of psoriasis refractory to biologic therapy: the University of California San Francisco experience. J Am Acad Dermatol (2013) 1.39
PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema. Skinmed (2005) 1.39
Phototherapy trends in dermatology. J Dermatolog Treat (2013) 1.38
Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet (2005) 1.37
Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol (2007) 1.37
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol (2004) 1.36
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol (2007) 1.35
Use of electronic medical records differs by specialty and office settings. J Am Med Inform Assoc (2013) 1.34
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol (2007) 1.34
The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol (2006) 1.34
Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol (2004) 1.32
Quality of life in patients with psoriasis. Health Qual Life Outcomes (2006) 1.31